2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.26 Cooper

PP01.26 Cooper - Abstract

Pdf Summary

This study examines the efficacy of pre-treatment neutrophil-lymphocyte ratio (NLR) as a prognostic biomarker in non-small cell lung cancer (NSCLC) patients treated with third-generation EGFR Tyrosine Kinase Inhibitors. The research, conducted at the Norris Comprehensive Cancer Center and Los Angeles General Medical Center, included 151 NSCLC patients treated with TKIs targeting known EGFR mutations between 2017-2023. The study found that baseline NLR less than 5 was associated with a longer median progression-free survival (PFS) in patients treated with 1st or 2nd generation TKIs, but this correlation was not significant in patients treated with third-generation TKIs like Osimertinib. Additionally, combining baseline albumin levels with NLR as a predictive factor showed worse PFS in some patients, although this was not consistently seen in the third-generation TKI group. The findings suggest that third-generation EGFR-targeting TKIs may be more effective in treating patients with poor survival predictors based on laboratory data. However, further prospective studies are needed to confirm these results and investigate the potential improved efficacy of third-generation TKIs.

Keywords

Neutrophil-lymphocyte ratio

NSCLC

EGFR Tyrosine Kinase Inhibitors

Norris Comprehensive Cancer Center

Los Angeles General Medical Center

EGFR mutations

Progression-free survival

Osimertinib

Albumin levels

Predictive factors